Andy Deig joined Immatics in March 2026 and brings over 18 years of experience in the pharmaceutical and biotechnology industry.
Prior to joining Immatics, he served as Senior Vice President, Strategic Finance at Immunovant where he led strategic planning, facilitated equity financings of ~$0.9B, and oversaw the procurement function, which enabled significant growth of the organization and clinical development pipeline execution. Previously, as Vice President, FP&A and Chief of Staff to the CEO, he led financial planning, orchestrated executive leadership team operations, drove key corporate initiatives and spearheaded Board of Directors engagement. Prior to Immunovant, Andy spent over a decade at Eli Lilly and Company in progressive financial and commercial roles spanning R&D, manufacturing, marketing and sales.
Andy Deig holds an MBA in Healthcare Sector Management from Duke University’s Fuqua School of Business and a bachelor’s degree in economics and German from Wabash College.